References in periodicals archive ?
About DebRA The Dystrophic Epidermolysis Bullosa Research Association of America (DebRA), is the only national non-profit dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB) - The Worst Disease You've Never Heard Of.
Proceeds from the event benefit d eb ra of America , the only national nonprofit dedicated to funding research for treatments and a cure, while providing supportive services and programs for those who suffer from the rare and painful genetic disorder, Epidermolysis Bullosa.
Scioderm's main focus is the treatment of Epidermolysis Bullosa (EB).
Mats has been instrumental in helping d eb ra of America raise awareness for Epidermolysis Bullosa and funds for research and the supportive services and programs.
Alan Arbuckle, MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado.
The work was sponsored in part by the Department of Veterans Affairs, the Epidermolysis Bullosa Medical Research Foundation, a Schroedinger grant from the FWF of Austria and grants from the National Institutes of Health.
will be holding the biennial DebRA Patient Care Conference(PCC) for the children and families affected by Epidermolysis Bullosa (EB) from July 30 through August 1 at the Gaylord Palms Resort and Convention Center in Orlando/Kissimmee, Florida.
com) announced it is clear to begin its third Phase II clinical trial to test its drug, Thymosin beta 4 (TB4), for the treatment of patients with epidermolysis bullosa (EB).
June 19, 2012 /PRNewswire-iReach/ -- Scioderm today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of topical administration of SD-101, a dermal pharmaceutical in development for treatment of chronic wounds and lesions in children with various types of Epidermolysis Bullosa.
In 2004, TB4 was designated an "Orphan Drug" by the FDA for the treatment of patients with epidermolysis bullosa.
Most of the patients enrolled in the Australian trials were patients suffering from Epidermolysis Bullosa (EB), a rare genetic disorder which causes major breakdowns of the skin similar to those caused by severe burns.
19, 2015 /PRNewswire/ -- EB Research Partnership("EBRP") -- the nation's largest not-for-profit organization dedicated to curing epidermolysis bullosa ("EB"), a rare and debilitating skin disorder -- announced today that it has secured a $3 million individual gift from the Deshe Family, the largest of its kind ever given to an EB-related cause.

Full browser ?